Impact of Genetic Polymorphisms on Opioid Misuse: A Scoping Review

Abstract

We conducted a scoping review on genetic polymorphisms associated with opioid intake-related adverse patient outcomes including behavioral, physiological and clinical outcomes. We searched for studies on Medline^®, EMBASE^®, CINAHL^®, Psychinfo^® and SNPedia^® from January 2006 to January 2018. Our study identified 33 genes and 71 SNPs associated with opioid-intake related adverse patient outcomes: four studies showing associations of nine SNPs with clinical events (e.g., arrhythmia, length of stay and deaths); six studies showing associations of 13 SNPs with respiratory depression and 25 studies showing associations of 50 SNPs with opioid misuse behaviors. Available pharmacogenetic-tests covered polymorphisms associated with opioids metabolism and ignored polymorphisms associated with opioids transport, receptor-binding and signaling that were linked with respiratory depression and misuse behaviors.

Keywords::

• fentanyl
• morphine
• SNPs

Acknowledgments

The authors are grateful to the National Institute of Drug Abuse and the Purdue Pharma, Medical Affairs Department for their inputs on the main findings of this study.

Financial & competing interests disclosure

This study has not received any extramural funding. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The authors are grateful to the National Institute of Drug Abuse and the Purdue Pharma, Medical Affairs Department for their inputs on the main findings of this study.